These medications excel at glycemic control and produce substantial weight loss through mechanisms centered on insulin secretion enhancement, glucagon suppression, and central appetite regulation via GLP-1 pathways
BREAKING NEWS APRIL 15, 2026 - In a welcome announcement to the SSRP community, the FDA reported today that it will imminently remove the following bulk drug substances from category 2: BPC-157, LL-37, DiHexa, DSIP, Epitalon, *GHK-Cu (injectable only), KPV, PEG-MGF, Melanotan II, MOTs-C, Semax, and TB-500
To schedule your personal consultation at our Berkeley office, please call (510) 637-9394 or submit our online contact form
If you have asthma, be cautious when considering glutathione supplementation and consult with your healthcare provider
A rich, oil-based formula helps lock in hydration and strengthen the skin barrier
At TrimrX, we focus on what the data unequivocally supports